Promega Collaborates with Oxford to Accelerate Precision Medicine Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Businesswire
- Technological Breakthrough: Promega's collaboration with SUNY Stony Brook and the University of Oxford utilizes NanoBRET® technology to characterize inhibitors targeting cancer cells directly in live cells, revealing the connection between drug efficacy and tumor metabolic state, thus advancing precision oncology.
- Target Discovery: The study focuses on the PRMT5 protein, identifying a key vulnerability in approximately 10-15% of cancers where MTAP gene deletion alters PRMT5's interaction, potentially offering new strategies for cancer treatment.
- Biosensor Application: The CBH-002 probe developed by Oxford can measure PRMT5 inhibitor activity in live cells, demonstrating how MTA influences drug selectivity, paving the way for highly targeted therapies for MTAP-deleted cancers.
- Collaboration Between Academia and Industry: This research underscores the value of academic-industry partnerships, combining expertise in chemical biology and assay design to drive the development of future precision medicines, which holds significant strategic implications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGEN
Wall Street analysts forecast PGEN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.160
Low
9.00
Averages
9.00
High
9.00
Current: 4.160
Low
9.00
Averages
9.00
High
9.00
About PGEN
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precigen Reports Strong Q1 2026 Earnings, Shares Surge
- Strong Financial Performance: Precigen reported $23.3 million in revenue for Q1 2026, a $21.9 million increase year-over-year, exceeding consensus estimates by $2.5 million, indicating robust demand for its newly launched cancer therapy, Papzimeos.
- Significant Reduction in Net Loss: The company's net loss fell approximately 85% year-over-year to $7.9 million, reflecting effective cost control and rapid revenue growth, which enhances investor confidence in its future profitability.
- Market Expansion Plans: CEO Helen Sabzevari stated that Precigen aims to explore opportunities for Papzimeos in overseas markets and the pediatric population, further driving revenue growth and increasing market share.
- Analyst Optimism: Seeking Alpha analyst Sean Daly reaffirmed his Buy rating on Precigen, noting that the company demonstrated real commercial validation in its Q1 earnings call, and he expects the market to recognize its future earnings potential.
See More
Citizens Raises Precigen Price Target to $11 Amid Strong Sales
- Price Target Increase: Citizens raised Precigen's price target from $9 to $11 while maintaining an 'Outperform' rating, indicating a potential upside of 165% from Wednesday's closing price, reflecting strong market confidence in the company.
- Sales Exceed Expectations: Precigen's Papzimeos generated $21.6 million in sales, significantly surpassing Wall Street's estimate of $20.8 million, contributing to a total revenue of $23.3 million in Q1, showcasing robust performance in the biotech sector.
- Investor Sentiment Soars: Precigen saw a surge of over 660% in message volume on Stocktwits in the past 24 hours, with investor sentiment shifting from 'bullish' to 'extremely bullish', indicating optimism surrounding its HPV cancer therapy candidate PRGN-2009.
- Positive Future Outlook: Precigen anticipates reaching cash flow break-even by the end of 2026, supported by existing cash reserves and revenue from Papzimeos sales, suggesting strong potential for sustainable growth in the coming years.
See More
Precigen Inc Reports Strong Q1 2026 Revenue Growth
- Significant Revenue Growth: Precigen Inc reported net product revenue of $21.6 million for Q1 2026 from Papcimius, a substantial increase from $3.4 million in Q4 2025, indicating strong market demand and uptake that is expected to drive future revenue growth.
- FDA Full Approval: The full approval of Papcimius by the FDA, with no restrictions on the number of surgeries prior to treatment, has facilitated rapid adoption in major medical centers and community practices, further strengthening the company's position in the competitive biopharmaceutical market.
- Strong Financial Position: The company holds $56.7 million in cash and cash equivalents, with expectations to reach cash flow breakeven by the end of 2026, indicating that it can support its operations and R&D activities without needing additional funding, thereby enhancing investor confidence.
- Rising Operational Costs: Despite revenue growth, Precigen reported an operating loss of $6 million for Q1, with R&D expenses expected to rise, potentially impacting future profitability, and the lack of specific guidance for future quarters adds uncertainty to market expectations.
See More
Precigen Reports Strong Q1 2026 Earnings with $21.6M in Revenue
- Significant Revenue Growth: Precigen reported net product revenue of $21.6 million for Q1 2026, a substantial increase from $3.4 million in Q4 2025, indicating strong market demand and product acceptance, which bodes well for future revenue growth.
- Patient Registration Update: Currently, approximately 400 patients are registered for treatment, with 25% in community settings, reflecting positive progress in expanding market coverage and patient base, which is expected to further drive sales growth.
- Strong Financial Position: Total revenue for the first quarter was $23.3 million, with an operating loss of $6 million and a net loss of $7.9 million, demonstrating the company's efforts in cost control while maintaining $56.7 million in cash and cash equivalents to support future operations.
- Positive Future Outlook: Management anticipates achieving cash flow breakeven by the end of 2026 and plans to initiate a pediatric trial for PAPZIMEOS in Q4 2026, indicating confidence in new product demand and strategic market focus.
See More
Precigen Q1 Earnings Preview and Outlook
- Earnings Announcement: Precigen (PGEN) is set to release its Q1 2023 earnings on May 13th after market close, with consensus EPS estimate at -$0.04 and revenue expected to reach $20.8 million, reflecting the company's commitment to financial transparency.
- Historical Performance: Over the past two years, PGEN has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating challenges in meeting financial targets that could affect investor confidence.
- New Product Launch: Precigen anticipates Q1 revenue exceeding $18 million, driven by the accelerated launch of PAPZIMEOS immunotherapy and broad U.S. payer coverage, which could provide new growth momentum for the company.
- Market Reaction: Following positive outlooks for PAPZIMEOS, Precigen's stock gained after the 2025 earnings report, indicating a favorable market response to its new product, which may enhance the company's future market performance.
See More
Precigen's PAPZIMEOS Sees Strong Sales Growth
- Strong Sales Performance: Precigen reported net product sales of $3.4 million for PAPZIMEOS in Q4 2025, with shipments starting in November, indicating robust market demand and marking a successful transition from R&D to revenue generation.
- Patient Enrollment Surge: The enrollment at Precigen's patient hub surpassed 300 in Q4, reflecting significant interest from both physicians and patients, which further enhances the product's market acceptance and utilization.
- Optimistic Revenue Outlook: The company anticipates revenues exceeding $18 million in Q1 2026, driven by the strong momentum of PAPZIMEOS, showcasing the growth potential and market confidence in the biopharmaceutical sector.
- Successful Strategic Shift: CEO Helen Sabzevari emphasized that the successful launch of PAPZIMEOS represents a pivotal milestone for the company, indicating its transformation from a research-focused entity to a product revenue-generating biotech firm.
See More
Precigen Reports Strong Q1 2026 Earnings, Shares Surge
- Strong Financial Performance: Precigen reported $23.3 million in revenue for Q1 2026, a $21.9 million increase year-over-year, exceeding consensus estimates by $2.5 million, indicating robust demand for its newly launched cancer therapy, Papzimeos.
- Significant Reduction in Net Loss: The company's net loss fell approximately 85% year-over-year to $7.9 million, reflecting effective cost control and rapid revenue growth, which enhances investor confidence in its future profitability.
- Market Expansion Plans: CEO Helen Sabzevari stated that Precigen aims to explore opportunities for Papzimeos in overseas markets and the pediatric population, further driving revenue growth and increasing market share.
- Analyst Optimism: Seeking Alpha analyst Sean Daly reaffirmed his Buy rating on Precigen, noting that the company demonstrated real commercial validation in its Q1 earnings call, and he expects the market to recognize its future earnings potential.
See More
Citizens Raises Precigen Price Target to $11 Amid Strong Sales
- Price Target Increase: Citizens raised Precigen's price target from $9 to $11 while maintaining an 'Outperform' rating, indicating a potential upside of 165% from Wednesday's closing price, reflecting strong market confidence in the company.
- Sales Exceed Expectations: Precigen's Papzimeos generated $21.6 million in sales, significantly surpassing Wall Street's estimate of $20.8 million, contributing to a total revenue of $23.3 million in Q1, showcasing robust performance in the biotech sector.
- Investor Sentiment Soars: Precigen saw a surge of over 660% in message volume on Stocktwits in the past 24 hours, with investor sentiment shifting from 'bullish' to 'extremely bullish', indicating optimism surrounding its HPV cancer therapy candidate PRGN-2009.
- Positive Future Outlook: Precigen anticipates reaching cash flow break-even by the end of 2026, supported by existing cash reserves and revenue from Papzimeos sales, suggesting strong potential for sustainable growth in the coming years.
See More
Precigen Inc Reports Strong Q1 2026 Revenue Growth
- Significant Revenue Growth: Precigen Inc reported net product revenue of $21.6 million for Q1 2026 from Papcimius, a substantial increase from $3.4 million in Q4 2025, indicating strong market demand and uptake that is expected to drive future revenue growth.
- FDA Full Approval: The full approval of Papcimius by the FDA, with no restrictions on the number of surgeries prior to treatment, has facilitated rapid adoption in major medical centers and community practices, further strengthening the company's position in the competitive biopharmaceutical market.
- Strong Financial Position: The company holds $56.7 million in cash and cash equivalents, with expectations to reach cash flow breakeven by the end of 2026, indicating that it can support its operations and R&D activities without needing additional funding, thereby enhancing investor confidence.
- Rising Operational Costs: Despite revenue growth, Precigen reported an operating loss of $6 million for Q1, with R&D expenses expected to rise, potentially impacting future profitability, and the lack of specific guidance for future quarters adds uncertainty to market expectations.
See More
Precigen Reports Strong Q1 2026 Earnings with $21.6M in Revenue
- Significant Revenue Growth: Precigen reported net product revenue of $21.6 million for Q1 2026, a substantial increase from $3.4 million in Q4 2025, indicating strong market demand and product acceptance, which bodes well for future revenue growth.
- Patient Registration Update: Currently, approximately 400 patients are registered for treatment, with 25% in community settings, reflecting positive progress in expanding market coverage and patient base, which is expected to further drive sales growth.
- Strong Financial Position: Total revenue for the first quarter was $23.3 million, with an operating loss of $6 million and a net loss of $7.9 million, demonstrating the company's efforts in cost control while maintaining $56.7 million in cash and cash equivalents to support future operations.
- Positive Future Outlook: Management anticipates achieving cash flow breakeven by the end of 2026 and plans to initiate a pediatric trial for PAPZIMEOS in Q4 2026, indicating confidence in new product demand and strategic market focus.
See More
Precigen Q1 Earnings Preview and Outlook
- Earnings Announcement: Precigen (PGEN) is set to release its Q1 2023 earnings on May 13th after market close, with consensus EPS estimate at -$0.04 and revenue expected to reach $20.8 million, reflecting the company's commitment to financial transparency.
- Historical Performance: Over the past two years, PGEN has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating challenges in meeting financial targets that could affect investor confidence.
- New Product Launch: Precigen anticipates Q1 revenue exceeding $18 million, driven by the accelerated launch of PAPZIMEOS immunotherapy and broad U.S. payer coverage, which could provide new growth momentum for the company.
- Market Reaction: Following positive outlooks for PAPZIMEOS, Precigen's stock gained after the 2025 earnings report, indicating a favorable market response to its new product, which may enhance the company's future market performance.
See More
Precigen's PAPZIMEOS Sees Strong Sales Growth
- Strong Sales Performance: Precigen reported net product sales of $3.4 million for PAPZIMEOS in Q4 2025, with shipments starting in November, indicating robust market demand and marking a successful transition from R&D to revenue generation.
- Patient Enrollment Surge: The enrollment at Precigen's patient hub surpassed 300 in Q4, reflecting significant interest from both physicians and patients, which further enhances the product's market acceptance and utilization.
- Optimistic Revenue Outlook: The company anticipates revenues exceeding $18 million in Q1 2026, driven by the strong momentum of PAPZIMEOS, showcasing the growth potential and market confidence in the biopharmaceutical sector.
- Successful Strategic Shift: CEO Helen Sabzevari emphasized that the successful launch of PAPZIMEOS represents a pivotal milestone for the company, indicating its transformation from a research-focused entity to a product revenue-generating biotech firm.
See More
